These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9091060)

  • 1. Will killing the last HIV1 particle cure AIDS patients? II: Second Part. Decrease of viral load and of T-suppressor cells, and increase of the cytotoxic cells, without effect on CD4, after the use of 10 virostatics applied in 3 or 4 drug combinations of different sequences. The time for CD4 immunotherapy?
    Mathé G; Colasanté U; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(10):473-9. PubMed ID: 9091060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Will killing the last HIV1 particle cure AIDS patients? Doesn't CMV activation and/or a graft-versus-host component of the disease, also have to be considered? I. First of two parts.
    Mathé G
    Biomed Pharmacother; 1996; 50(5):185-206. PubMed ID: 8949400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinations of three or four HIV virostatics applied in short sequences which differ from each other by drug rotation. Preliminary results of the viral loads and CD4 numbers.
    Mathé G; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1997; 51(10):417-26. PubMed ID: 9863499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.
    Mathe G; Morette C; Hallard M; Pontiggia P; Blanquet D; Hage F
    Acta Pharmacol Sin; 2002 Jan; 23(1):1-15. PubMed ID: 11860730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of four virostatics applied in rotational sequences induce an exponential VL regression curve, the first part of which is rapidly decreasing to a PCR-undetectable level, while the last part is insensitive to the model. Indications for virostatic and immunotherapeutic reinforcements?
    Mathé G
    Biomed Pharmacother; 1999 Mar; 53(2):57-62. PubMed ID: 10337459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Deep lung--cellular reaction to HIV].
    Tavares Marques MA; Alves V; Duque V; Botelho MF
    Rev Port Pneumol; 2007; 13(2):175-212. PubMed ID: 17492233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.
    Sánchez-Ramón S; Bellón JM; Resino S; Cantó-Nogués C; Gurbindo D; Ramos JT; Muñoz-Fernández MA
    Pediatrics; 2003 Feb; 111(2):E168-75. PubMed ID: 12563091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.
    Evans TG; Bonnez W; Soucier HR; Fitzgerald T; Gibbons DC; Reichman RC
    Antiviral Res; 1998 Oct; 39(3):163-73. PubMed ID: 9833957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypothetical reasons of the HIV1-AIDS "tritherapy" failure. A challenging model.
    Mathé G
    Biomed Pharmacother; 1997; 51(10):413-6. PubMed ID: 9863498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell response of advanced aids patients after highly active antiretroviral therapy.
    Wang AX; Li TS; Cao YZ; Han Y; Qiu ZF; Xie J
    Chin Med Sci J; 2005 Dec; 20(4):223-5. PubMed ID: 16422247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of cancer cells and of HIV1: the problems of cell and virus rebounds and of latency.
    Mathé G
    Biomed Pharmacother; 1998; 52(10):413-20. PubMed ID: 9921409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characteristics of immunophenotypic alterations in 263 HIV/AIDS patients].
    Xie J; Qiu ZF; Li TS; Han Y; Zuo LY; Ma XJ; Liu ZY; Wang AX
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):965-9. PubMed ID: 16759536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.
    Fahey JL; Prince H; Weaver M; Groopman J; Visscher B; Schwartz K; Detels R
    Am J Med; 1984 Jan; 76(1):95-100. PubMed ID: 6229182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative changes in T helper inducer (CD4+ CD45RA-), T suppressor inducer (CD4+ CD45RA+), T suppressor (CD8+ CD11b+), and T cytotoxic (CD8+ CD11b-) subsets in human immunodeficiency virus infection.
    Reddy MM; Grieco MH
    J Clin Lab Anal; 1991; 5(2):96-100. PubMed ID: 2023064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.